Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vera Therapeutics, Inc. - Class A Common Stock
(NQ:
VERA
)
48.71
+1.02 (+2.14%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vera Therapeutics, Inc. - Class A Common Stock
< Previous
1
2
3
4
Next >
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
January 07, 2026
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
December 09, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
December 08, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
November 26, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
November 24, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
November 10, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
November 07, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
November 06, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
October 22, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
October 17, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate at Upcoming Investor Conferences
August 26, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 05, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 09, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
June 03, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
June 02, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
May 06, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 09, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
April 03, 2025
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 11, 2025
From
Vera Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit